| Literature DB >> 33836962 |
Zachary Colbaugh1, Thomas Evans Watts2, Mustafa I Ahmed2, Dylan R Addis3.
Abstract
Herein the case of a patient with a prior history of heparin-induced thrombocytopenia who underwent percutaneous mitral valve edge-to-edge repair that was followed by a tricuspid edge-to-edge repair two months later is presented. Recommendations exist for systemic anticoagulant alternatives for percutaneous mitral valve edge-to-edge repair with the MitraClip device (Abbott, Chicago, IL), but minimal guidance and experience are present regarding alternative systemic anticoagulation during the performance of right-sided interventions, including tricuspid edge-to-edge repair (TriClip; Abbott). Notably, there is no clear consensus regarding the use of an alternative anticoagulant in the catheter flush solution for the delivery systems used during these procedures, particularly for right-sided interventions.Entities:
Keywords: MitraClip; TriClip; anticoagulation; bivalirudin; heparin-induced thrombocytopenia; percutaneous valve repair
Mesh:
Substances:
Year: 2021 PMID: 33836962 PMCID: PMC8419205 DOI: 10.1053/j.jvca.2021.03.004
Source DB: PubMed Journal: J Cardiothorac Vasc Anesth ISSN: 1053-0770 Impact factor: 2.894